AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22584689 — intervention group
Group type: EXPERIMENTAL
Intervention: Lornoxicam 16 mg then 8 mg after 12 h
Number of subjects: 60
Study 22584689 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol 1 g every 6 h
Number of subjects: 60
Study 22584689 — intervention group
Group type: COMPARATOR
Intervention: Isotonic saline (control group)
Number of subjects: 60
Study 22584689 — intervention group
Group type: EXPERIMENTAL
Intervention: Lornoxicam
Number of subjects: 60
Study 22584689 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol
Number of subjects: 60
Study 21097402 — intervention group
Group type: EXPERIMENTAL
Intervention: Shuganlipi decoction
Number of subjects: 86
Study 21097402 — intervention group
Group type: COMPARATOR
Intervention: Routine western medication
Number of subjects: 86
Study 17277593 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength Training (ST)
Number of subjects: 11
Study 17277593 — intervention group
Group type: COMPARATOR
Intervention: Single Resistance Exercise (RE) bout
Number of subjects: 11
Study 17277593 — intervention group
Group type: COMPARATOR
Intervention: Resistance Exercise (RE) before ST
Number of subjects: 11
Study 17277593 — intervention group
Group type: COMPARATOR
Intervention: Resistance Exercise (RE)
Number of subjects: 11
Study 16254092 — intervention group
Group type: EXPERIMENTAL
Intervention: Belief in meritocracy
Number of subjects: 0
Study 16254092 — intervention group
Group type: EXPERIMENTAL
Intervention: Disbelief in meritocracy
Number of subjects: 0
Study 16254092 — intervention group
Group type: COMPARATOR
Intervention: Belief in meritocracy (control condition)
Number of subjects: 0
Study 16254092 — intervention group
Group type: COMPARATOR
Intervention: Disbelief in meritocracy (control condition)
Number of subjects: 0
Study 12374324 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesencephalic dopamine system for reinforcement learning
Number of subjects: 0
Study 12374324 — intervention group
Group type: EXPERIMENTAL
Intervention: Generic error-processing system associated with the anterior cingulate cortex
Number of subjects: 0
Study 9935005 — intervention group
Group type: EXPERIMENTAL
Intervention: Biphasic shocks at 5 seconds of VF
Number of subjects: 30
Study 9935005 — intervention group
Group type: EXPERIMENTAL
Intervention: Biphasic shocks at 10 seconds of VF
Number of subjects: 30
Study 9935005 — intervention group
Group type: EXPERIMENTAL
Intervention: Biphasic shocks at 20 seconds of VF
Number of subjects: 30
Study 9935005 — intervention group
Group type: EXPERIMENTAL
Intervention: Increase in DFT observed in patients
Number of subjects: 30
Study 7766740 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg once daily
Number of subjects: 242
Study 7766740 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine 150 mg twice daily
Number of subjects: 242
Study 2148177 — intervention group
Group type: EXPERIMENTAL
Intervention: cetirizine 5 mg, 10 mg, or 20 mg
Number of subjects: 60
Study 2148177 — intervention group
Group type: EXPERIMENTAL
Intervention: hydroxyzine 25 mg
Number of subjects: 60
Study 2148177 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 60
Study 7440519 — intervention group
Group type: EXPERIMENTAL
Intervention: Trazodone
Number of subjects: 184
Study 7440519 — intervention group
Group type: COMPARATOR
Intervention: Amitriptyline
Number of subjects: 184
Study 7440519 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 184
Study 31959151 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial support group intervention
Number of subjects: 742
Study 31959151 — intervention group
Group type: COMPARATOR
Intervention: Improved standard of mental health care
Number of subjects: 742
Study 30632972 — intervention group
Group type: EXPERIMENTAL
Intervention: BlueStar mobile app for 6 months (immediate treatment group)
Number of subjects: 223
Study 30632972 — intervention group
Group type: COMPARATOR
Intervention: Usual care for 3 months followed by BlueStar mobile app for 3 months (wait-list control group)
Number of subjects: 223
Study 30632972 — intervention group
Group type: EXPERIMENTAL
Intervention: Exploratory analysis of app usage
Number of subjects: 223
Study 28759262 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole (APZ)
Number of subjects: 59
Study 28759262 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study 25754454 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical 0.1% oxybutynin hydrochloride (10 ml, three times per day for 28 days)
Number of subjects: 35
Study 25754454 — intervention group
Group type: COMPARATOR
Intervention: Oral 5 mg oxybutynin hydrochloride (three times per day for 28 days)
Number of subjects: 35
Study 25754454 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical 0.1% oxybutynin hydrochloride
Number of subjects: 35
Study 25754454 — intervention group
Group type: COMPARATOR
Intervention: Oral 5 mg oxybutynin hydrochloride
Number of subjects: 35
Study 25031529 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-blocker plus antidiuretic agent
Number of subjects: 405
Study 25031529 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-blocker plus anticholinergic agent
Number of subjects: 405
Study 25031529 — intervention group
Group type: COMPARATOR
Intervention: Alpha-blocker
Number of subjects: 405
Study 22367233 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep Education Program (SEP)
Number of subjects: 47
Study 22367233 — intervention group
Group type: COMPARATOR
Intervention: Usual care control
Number of subjects: 47
Study 19085703 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan
Number of subjects: 94
Study 19085703 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan
Number of subjects: 94
Study 19085703 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 94
Study 17134951 — intervention group
Group type: EXPERIMENTAL
Intervention: Enriched eggs (5 per week for 3 weeks)
Number of subjects: 25
Study 17134951 — intervention group
Group type: COMPARATOR
Intervention: Normal eggs (5 per week for 3 weeks)
Number of subjects: 25
Study 16363623 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacrimal scintigraphy in patients with dry eye syndrome
Number of subjects: 21
Study 16363623 — intervention group
Group type: COMPARATOR
Intervention: Lacrimal scintigraphy in normal subjects
Number of subjects: 21
Study 16363623 — intervention group
Group type: EXPERIMENTAL
Intervention: Schirmer‐1 test in patients with dry eye syndrome
Number of subjects: 21
Study 16363623 — intervention group
Group type: COMPARATOR
Intervention: Schirmer‐1 test in normal subjects
Number of subjects: 21
Study 16363623 — intervention group
Group type: EXPERIMENTAL
Intervention: BUT in patients with dry eye syndrome
Number of subjects: 21
Study 16363623 — intervention group
Group type: COMPARATOR
Intervention: BUT in normal subjects
Number of subjects: 21
Study 16363623 — intervention group
Group type: EXPERIMENTAL
Intervention: Rose bengal staining in patients with dry eye syndrome
Number of subjects: 21
Study 16363623 — intervention group
Group type: COMPARATOR
Intervention: Rose bengal staining in normal subjects
Number of subjects: 21
Study 12412821 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid 4 mg/5 min
Number of subjects: 36
Study 12412821 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid (all doses)
Number of subjects: 36
Study 10030179 — intervention group
Group type: EXPERIMENTAL
Intervention: Slide-tape with information on postoperative rehabilitation
Number of subjects: 222
Study 10030179 — intervention group
Group type: EXPERIMENTAL
Intervention: Training in Benson's Relaxation Response with bedside audiotape
Number of subjects: 222
Study 1519474 — intervention group
Group type: EXPERIMENTAL
Intervention: Atraumatic Sprotte needle (22G)
Number of subjects: 75
Study 1519474 — intervention group
Group type: COMPARATOR
Intervention: Sharp Quincke needle (22G)
Number of subjects: 75
Study 6388080 — intervention group
Group type: EXPERIMENTAL
Intervention: Noradrenaline (8 mg in 100 ml cold saline)
Number of subjects: 42
Study 6388080 — intervention group
Group type: COMPARATOR
Intervention: Cold saline alone
Number of subjects: 42
Study 31748905 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy with pentoxifylline and vitamin E
Number of subjects: 60
Study 31748905 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy (control group)
Number of subjects: 60
Study 28919128 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin (≤600mg/d)
Number of subjects: 54
Study 28919128 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 26818372 — intervention group
Group type: EXPERIMENTAL
Intervention: Swaddling
Number of subjects: 54
Study 26818372 — intervention group
Group type: COMPARATOR
Intervention: Control (standard care)
Number of subjects: 54
Study 25335245 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture at stellate ganglion (observation group)
Number of subjects: 80
Study 25335245 — intervention group
Group type: COMPARATOR
Intervention: Conventional acupuncture (control group)
Number of subjects: 80
Study 22521705 — intervention group
Group type: EXPERIMENTAL
Intervention: Resin‐modified GIC (RM‐GIC) open laminate plus resin composite
Number of subjects: 24
Study 22521705 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional GIC open laminate plus resin composite
Number of subjects: 24
Study 22521705 — intervention group
Group type: COMPARATOR
Intervention: Resin composite alone
Number of subjects: 24
Study 22521705 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 24
Study 22521705 — intervention group
Group type: EXPERIMENTAL
Intervention: Laminate restorations
Number of subjects: 24
Study 22521705 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional GIC
Number of subjects: 24
Study 19763661 — intervention group
Group type: COMPARATOR
Intervention: Post-PCI TIMI flow grade 1
Number of subjects: 1761
Study 19763661 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-PCI TIMI flow grade 0
Number of subjects: 1761
Study 19763661 — intervention group
Group type: COMPARATOR
Intervention: Post-PCI TIMI flow grade 2
Number of subjects: 1761
Study 19763661 — intervention group
Group type: COMPARATOR
Intervention: Post-PCI TIMI flow grade 3
Number of subjects: 1761
Study 19067804 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger women (<50 years old)
Number of subjects: 88
Study 16650725 — intervention group
Group type: EXPERIMENTAL
Intervention: Letter Memory Test (LMT)
Number of subjects: 0
Study 16650725 — intervention group
Group type: EXPERIMENTAL
Intervention: Letter Memory Test (LMT) with difficulty manipulations
Number of subjects: 0
Study 12784167 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery disease patients
Number of subjects: 22
Study 12784167 — intervention group
Group type: COMPARATOR
Intervention: Healthy control subjects
Number of subjects: 22
Study 10858991 — intervention group
Group type: EXPERIMENTAL
Intervention: CM challenge after 12 months of CM-free diet
Number of subjects: 86
Study 10858991 — intervention group
Group type: EXPERIMENTAL
Intervention: CM challenge
Number of subjects: 86
Study 10858991 — intervention group
Group type: COMPARATOR
Intervention: Immunologic tests (IgE, RAST, cutaneous prick tests)
Number of subjects: 86
Study 9279213 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled ET-1 (doubling dose range, 0.96 to 15.36 nmol)
Number of subjects: 13
Study 9279213 — intervention group
Group type: EXPERIMENTAL
Intervention: Methacholine (doubling dose range, 0.33 to 21.0 mumol)
Number of subjects: 13
Study 9279213 — intervention group
Group type: EXPERIMENTAL
Intervention: Albuterol
Number of subjects: 13
Study 9279213 — intervention group
Group type: COMPARATOR
Intervention: ET-1 (in healthy volunteers)
Number of subjects: 13
Study 9279213 — intervention group
Group type: COMPARATOR
Intervention: Noninvasive blood pressure measurements
Number of subjects: 13
Study 9279213 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma ET-1 measurements
Number of subjects: 13
Study 9279213 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen saturation monitoring
Number of subjects: 13
Study 8345072 — intervention group
Group type: EXPERIMENTAL
Intervention: Human chorionic gonadotrophin (HCG) (9000 IU)
Number of subjects: 16
Study 8345072 — intervention group
Group type: COMPARATOR
Intervention: Gonadotrophin-releasing hormone agonist (GnRHa)
Number of subjects: 16
Study 3729714 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose subcutaneous heparin therapy
Number of subjects: 0
Study 3729714 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 29024310 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive blood pressure control (SBP target <120 mm Hg)
Number of subjects: 9097
Study 29024310 — intervention group
Group type: COMPARATOR
Intervention: Standard blood pressure control (SBP target <140 mm Hg)
Number of subjects: 9097
Study 30193440 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotionally loaded stimulus - subject’s second name
Number of subjects: 0
Study 30193440 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotionally loaded stimulus - random shuffled letters of second name
Number of subjects: 0
Study 30193440 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotionally loaded stimulus - graphic representation of simple arithmetic expression with correct answer
Number of subjects: 0
Study 30193440 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotionally loaded stimulus - graphic representation of simple arithmetic expression with incorrect answer
Number of subjects: 0
Study 25274610 — intervention group
Group type: COMPARATOR
Intervention: Dasatinib (100 mg) alone
Number of subjects: 0
Study 25274610 — intervention group
Group type: EXPERIMENTAL
Intervention: Dasatinib (100 mg) with 1500 mg BHCl after rabeprazole pretreatment
Number of subjects: 0
Study 22462626 — intervention group
Group type: EXPERIMENTAL
Intervention: Vardenafil 5 mg/day
Number of subjects: 36
Study 22462626 — intervention group
Group type: EXPERIMENTAL
Intervention: Vardenafil 10 mg/day
Number of subjects: 36
Study 22462626 — intervention group
Group type: COMPARATOR
Intervention: Control group (no PDE5 inhibitors)
Number of subjects: 36
Study 20543734 — intervention group
Group type: EXPERIMENTAL
Intervention: Plyometric training (PT)
Number of subjects: 35
Study 20543734 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic weight training (DWT)
Number of subjects: 35
Study 20543734 — intervention group
Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 35
Study 18329596 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal weight and overweight women
Number of subjects: 349
Study 18329596 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese women
Number of subjects: 349
Study 18329596 — intervention group
Group type: EXPERIMENTAL
Intervention: Women with high depression scores
Number of subjects: 349
Study 15919441 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus (n = 50)
Number of subjects: 101
Study 15919441 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine microemulsion (n = 51)
Number of subjects: 101
Study 15919441 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus and Cyclosporine microemulsion
Number of subjects: 101
Study 12050248 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH) at a dose of 12.5 microg/kg per day for 12 months
Number of subjects: 16
Study 12050248 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 12 months
Number of subjects: 16
Study 12050248 — intervention group
Group type: EXPERIMENTAL
Intervention: Lean body mass
Number of subjects: 16
Study 12050248 — intervention group
Group type: EXPERIMENTAL
Intervention: DHEAS
Number of subjects: 16
Study 10332946 — intervention group
Group type: EXPERIMENTAL
Intervention: Naps
Number of subjects: 0
Study 10332946 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil (MODIODAL)
Number of subjects: 0
Study 10332946 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of naps and modafinil
Number of subjects: 0
Study 10332946 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 0
Study 9199744 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 0.01% with acyclovir 3%
Number of subjects: 45
Study 9199744 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen 0.03% with acyclovir 3%
Number of subjects: 45
Study 9199744 — intervention group
Group type: COMPARATOR
Intervention: Placebo with acyclovir 3%
Number of subjects: 45
Study 1712266 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilazapril 30mg
Number of subjects: 0
Study 1712266 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilazapril 4 mg
Number of subjects: 0
Study 1712266 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril 25 mg
Number of subjects: 0
Study 1712266 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril 10mg
Number of subjects: 0
Study 1712266 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilazapril (1.25, 3.75, 10 and 30mg)
Number of subjects: 0
Study 1712266 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilazapril
Number of subjects: 0
Study 1712266 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilazapril and Propranolol
Number of subjects: 0
Study 1712266 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 0
Study 1712266 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilazapril and Propranolol combination
Number of subjects: 0
Study 6857385 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment
Number of subjects: 280
Study 6857385 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 280
Study 31802111 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerometer-measured physical activity
Number of subjects: 79448
Study 31802111 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum iron
Number of subjects: 79448
Study 31802111 — intervention group
Group type: EXPERIMENTAL
Intervention: Body mass index (BMI)
Number of subjects: 79448
Study 31802111 — intervention group
Group type: EXPERIMENTAL
Intervention: Monounsaturated fat
Number of subjects: 79448
Study 31802111 — intervention group
Group type: EXPERIMENTAL
Intervention: Height
Number of subjects: 79448
Study 29482936 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacral Neuromodulation (SNM)
Number of subjects: 386
Study 29482936 — intervention group
Group type: COMPARATOR
Intervention: OnabotulinumtoxinA (BTX)
Number of subjects: 386
Study 27579803 — intervention group
Group type: EXPERIMENTAL
Intervention: MTPT and medicine ball exercises
Number of subjects: 100
Study 27579803 — intervention group
Group type: EXPERIMENTAL
Intervention: MTPT and stretching
Number of subjects: 100
Study 27579803 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control)
Number of subjects: 100
Study 25799801 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 20 microgram (0.4 ml) added to 0.5% bupivacaine heavy 2 ml (Group B)
Number of subjects: 70
Study 25799801 — intervention group
Group type: COMPARATOR
Intervention: 0.5% bupivacaine heavy 2.4 ml (Group A)
Number of subjects: 70
Study 21848849 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 ppm LA supplementation
Number of subjects: 160
Study 21848849 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 ppm LA supplementation
Number of subjects: 160
Study 21848849 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 ppm LA supplementation
Number of subjects: 160
Study 21848849 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-lipoic acid supplementation
Number of subjects: 160
Study 21848849 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight gains of piglets from sows fed 800 ppm LA diets
Number of subjects: 160
Study 21848849 — intervention group
Group type: EXPERIMENTAL
Intervention: LA-supplemented diets
Number of subjects: 160
Study 21848849 — intervention group
Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 160
Study 19268165 — intervention group
Group type: EXPERIMENTAL
Intervention: Program of Reinforcing Autonomy and Social Capacities (PRACS)
Number of subjects: 0
Study 17200838 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-0524 25 mg
Number of subjects: 15
Study 17200838 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-0524 100 mg
Number of subjects: 15
Study 17200838 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 15198882 — intervention group
Group type: EXPERIMENTAL
Intervention: Immune enhancing enteral diet
Number of subjects: 124
Study 15198882 — intervention group
Group type: COMPARATOR
Intervention: Isocaloric and isonitrogenous control enteral diet
Number of subjects: 124
Study 12365909 — intervention group
Group type: EXPERIMENTAL
Intervention: Verteporfin therapy
Number of subjects: 402
Study 12365909 — intervention group
Group type: COMPARATOR
Intervention: Placebo (original assignment)
Number of subjects: 402
Study 12365909 — intervention group
Group type: EXPERIMENTAL
Intervention: Verteporfin therapy (original assignment)
Number of subjects: 402
Study 16495883 — intervention group
Group type: EXPERIMENTAL
Intervention: Biological supplement (FloRelax®, Sanofi Winthrop) for 6 weeks
Number of subjects: 380
Study 16495883 — intervention group
Group type: COMPARATOR
Intervention: Control group (only diet)
Number of subjects: 380
Study 8087928 — intervention group
Group type: EXPERIMENTAL
Intervention: Chelation therapy (EDTA)
Number of subjects: 32
Study 8087928 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 32
Study 8087928 — intervention group
Group type: EXPERIMENTAL
Intervention: Chelation therapy
Number of subjects: 32
Study 2571759 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyrimethamine (25 mg weekly for suppressive prophylaxis)
Number of subjects: 88
Study 2571759 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyrimethamine (25 mg weekly after chloroquine 25 mg/kg)
Number of subjects: 88
Study 2571759 — intervention group
Group type: COMPARATOR
Intervention: Control (no prophylaxis after chloroquine 25 mg/kg)
Number of subjects: 88
Study 4835462 — intervention group
Group type: EXPERIMENTAL
Intervention: Early mobilization (mobilized immediately and discharged after 9 days)
Number of subjects: 189
Study 4835462 — intervention group
Group type: COMPARATOR
Intervention: Late mobilization (mobilized on the 9th day and discharged after 16 days)
Number of subjects: 189
Study 30894038 — intervention group
Group type: EXPERIMENTAL
Intervention: Assertive community treatment
Number of subjects: 366
Study 30894038 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 366
Study 30115183 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone application
Number of subjects: 42
Study 30115183 — intervention group
Group type: COMPARATOR
Intervention: Booklet (paper form)
Number of subjects: 42